Ontology highlight
ABSTRACT:
SUBMITTER: Peters S
PROVIDER: S-EPMC4367663 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
Peters Solange S Zimmermann Stefan S
Translational lung cancer research 20140401 2
HER2 mutations, largely exon 20 in-frame insertions, have been described as an oncogenic driver alteration in 1% to 4% of NSCLC, exclusively in adenocarcinoma histology. The prognostic implication of these alterations is not known. Phase I and II trial data suggest that afatinib, neratinib and dacomitinib have some activity in this molecular subgroup. No comparative data, or any data regarding the activity of pertuzumab or trastuzumab-emtansine is available. HER2 deregulation either by protein o ...[more]